Iain McGill | BiotechTV

top of page

Search

Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions

Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions

Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions

Iain McGill discusses the company's clinical liver transplant program, as well as IBD and type 1 diabetes programs.

Apr 29, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page